Display options
Share it on

Front Pharmacol. 2021 Aug 25;12:741485. doi: 10.3389/fphar.2021.741485. eCollection 2021.

Corrigendum: Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes.

Frontiers in pharmacology

Tracy Gasperetti, Tessa Miller, Feng Gao, Jayashree Narayanan, Elizabeth R Jacobs, Aniko Szabo, George N Cox, Christie M Orschell, Brian L Fish, Meetha Medhora

Affiliations

  1. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
  2. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.
  3. Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, United States.
  4. Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States.
  5. Department of Veterans Affairs, Research Service, Zablocki VAMC, Milwaukee, WI, United States.
  6. Institute for Health and Equity, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States.
  7. Bolder BioTechnology Inc., Boulder, CO, United States.
  8. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

PMID: 34512365 PMCID: PMC8424069 DOI: 10.3389/fphar.2021.741485

Abstract

[This corrects the article DOI: 10.3389/fphar.2021.634477.].

Copyright © 2021 Gasperetti, Miller, Gao, Narayanan, Jacobs, Szabo, Cox, Orschell, Fish and Medhora.

Keywords: acute radiation syndrome; delayed effects of acute radiation exposure; hematopoietic growth factor; lisinopril; mitigation; polypharmacy; radiation pneumonitis; supportive care

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publication Types